Member Info for B2HS2L

The STS ODD status may have sweetened a deal.

A deal the party concerned doesn't want discussed by the Avacta, despite development resources still being expended.

RNS 05.09.2022

Dr Alastair Smith, Chief Executive Officer of Avacta Group, commented:

"We are delighted to receive Orphan Drug Designation from the FDA for AVA6000, which is a reflection of the high quality of the preclinical data and the potential benefit the pre|CISION platform can bring to cancer patients.

"This designation provides tax credits and other incentives for drug developers addressing rare diseases. Most notably the Orphan Drug Designation will give Avacta, if AVA6000 is approved for treatment of soft tissue sarcoma, seven years of market exclusivity in the US, which is a significant commercial advantage."

+++

Ditto Christina Coughlin for Salivary Gland Cancer.

Also the ODD would provide the product validation from FDA we are interested in, and the second ODD for AVA6000.

CC today - Macro-economic problems in USA - for instance - increasing the time scale to acquire ODD status applied for by AVCT.

Also

SGC is the frontrunner because it'll get to the clinic quicker.

SGC. - The company have advised they have applied for ODD status.

The Sealion requires somewhere to parade his superior knowledge.

Share holder or not, he'll be back with new borothons, his ego will accept nothing less.

Get rid of Vinegrad and save all his wages. - How could we be worse off?

Placed the following in the investors feedback box:

I don't think many investors would disagree that Investor Relations are awful.

I have never received a response from ICR healthcare, and if that experience were read across to other investors, the ICR fee has been a drain on Avacta's dwindling cash pile, - and their services being unfit for purpose. - Certainly from an investor viewpoint.

I would request the company implement big improvements, including access to a list of FAQ's, which should be dynamic, and updated regularly.

As we approach many 'inflection points' in coming months, investor questions can be expected to increase, so please implement this ASAP.

...timing not right to be seen as an Amigo...

Firesale price due to Avacta's short runway?

1 hour presentation - with Q/A now 1hr 15 mins long.

Macro-economic problems in USA - I read that as Trump initiated.

CFO has not read any new information.

LLP - If you've enrolled patients, subsequently doing nothing is not an option?

SP static presently around 33p.

Slide 15 - 'FAP-Dox (AVA6000) partnering opportunity' Not visible as it was on past slide

We're otherwise still waiting for a concrete sign for how financing will be delivered.

I'm expecting there will be no financing signal, just an announcement that action has been taken and hello new era, - good or not so good.

An RNS to deal with audited preliminary results for year ended December 31, 2024 .

Any other news and we should look for a second RNS.

I'm expecting just one RNS tomorrow.

Improvement may have started around the time Trump started interfering with Bonds, interest rates etc, introducing market uncertainty and ruling by Executive Order?

Does that mean NASDAQ listing is still Avacta's goal, or have they reviewed the situation.

The question should be what should we investors expect him to do to answer investor questions.

The company provide:

* Quarterly Reports

* R&D Spotlights

But we don't have a working Investor Relations facility, yet the company is paying ICR healthcare to provide one.

This ball has been in Vinegrad's court way too long.

Please give consideration to the following:

I don't think many posters would disagree that Investor Relations are awful.

I have never received a response from ICR healthcare, and if read across to other investors, their fee has been a drain on Avacta's dwindling cash pile, - their services being unfit for purpose.

I have requested the company implement big improvements, including access to a list of FAQ's, which should be dynamic, and updated regularly.

As we approach many 'inflection points' in coming months, investor questions can be expected to increase.

+++

I would encourage you to send a request such as this to Investor Meet, as Avacta will be reading them today.

Questions on this subject can't be expected to be read out, but if enough investors send such encouragement, the company must surely act.

+++

Bella, agree with sacking Michael Vinegrad. - He's done sweet FA.

Insufficient positive news I'm afraid, D minus